b'RAANANA, Israel, April 12, 2021 /PRNewswire/ -- MyHomeDoc today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the MyHomeDoc system, which uses a multi-sensor device to remotely examine the mouth, throat, lungs, ears, heart, skin, abdomen, body temperature, and oxygen saturation (SpO2).\nThe device has been cleared for use in testing patients from 2 years old and older, making it suitable for a broad range of primary, chronic, and urgent care modalities for all demographics from pediatrics to seniors.\nIn a world where telehealth is becoming increasingly center stage, the shortcomings of the pre-existing model point to the need for a more seamless experience for everyone, which will make it possible for physicians to support their clinical decisions with clinically valid physical examination results.\nThe system utilizes a handheld device that pairs with a smartphone, user-friendly app, and includes a fully adaptable administration panel, best-in-class cybersecurity, and hybrid system architecture that integrates seamlessly with those of proprietary healthcare systems.\nIn addition, the system introduces multiple clinical workflows to connect patients and physicians with either offline (asynchronous) or online (synchronous) modes.\n"We are excited that this FDA clearancein conjunction with the CE mark that we received earlier this yearwill make it possible for more people to benefit from our user-friendly, cost-effective solution that elevates telehealth closer to the in-person clinic visit experience than ever before," says MyHomeDoc CEO Alon Natanson , "MyHomeDoc is an agent of change in the telehealth market enabling flexible business models based on innovative technology.